Our findings in a large, population-based registry of over 20 000 patients with a recent hospitalization for documented HF suggest that prescription of a non-selective beta-blocker is associated with ...

The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary ...

The appropriate duration of beta-blocker treatment after a heart attack (a myocardial infarction [MI]) is unknown in patients who do not need to take beta-blockers for another reason. In the ABYSS ...

The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear. We conducted a meta-analysis at the individual-patient level ...

Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality, new myocardial infarction (MI) and heart failure (HF) compared with no beta-blocker therapy in the subgroup of ...

Beta blockers are go-to meds for many people who've survived a heart attack. However, new Swedish research has found that they might not be needed for heart attack survivors whose hearts have retained ...

Beta-blockers provide no clinical benefit to post-MI patients with preserved left ventricular ejection fraction, according to a potentially paradigm-changing meta-analysis. The findings, published ...

Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a large multicenter ...

The cardiovascular safety of an interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction (MI) and there was no benefit to the ...